IG RD 002

Drug Profile

IG RD 002

Latest Information Update: 07 Oct 2009

Price : $50

At a glance

  • Originator Indigene Pharmaceuticals
  • Class Antiallergics; Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase Unknown Asthma; Perennial allergic rhinitis

Most Recent Events

  • 07 Oct 2009 Investigation in Perennial allergic rhinitis in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top